• Adipotide, also called FTPP, prohibitin-TP01, or TP01, is a synthetic chimeric pro-apoptotic peptidomimetic, not an endogenous signaling peptide and not a GLP-1, stimulant, lipolytic, or appetite suppressant.
• The core research identity is a fat-homing CKGGRAKDC motif joined by a GG linker to a pro-apoptotic KLAKLAK repeat payload; The monkey-paper sequence is commonly written CKGGRAKDC-GG-D(KLAKLAK)2.
• The scientific concept is targeted injury to white-adipose-tissue vasculature. This makes it qualitatively different from metabolic peptides that reversibly activate a receptor.
• Human development reached an initiated/dosed Phase 1 oncology/obesity safety study, but no peer-reviewed human obesity-efficacy or routine-safety results were identified. Do not summarize it as having established human fat-loss efficacy.
• Adipotide is a pro-apoptotic peptidomimetic aimed at adipose vasculature, not a metabolic hormone, GLP-1 alternative, or ordinary fat-loss peptide.

• The CKGGRAKDC homing sequence was selected for white-fat vasculature and is associated with prohibitin biology in adipose endothelial tissue.
• After binding/internalization, the KLAKLAK payload is intended to disrupt mitochondrial integrity and induce apoptosis in targeted vascular cells.
• The downstream result in animal models is loss or rarefaction of adipose blood supply, followed by reduction/resorption of the supported white fat depot.
• Prohibitin is a multifunctional protein and the PHB/ANXA2/CD36 system participates in fatty-acid transport. Do not overstate the target as universally fat-exclusive or human-validated for safe selectivity.
• The central idea is targeting prohibitin-associated markers in white-adipose vasculature and delivering a pro-apoptotic KLAKLAK payload after internalization. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Foundational rodent work used targeted ablation of adipose vasculature to reduce white fat in obesity models.
• The main nonhuman-primate study used 0.43 mg/kg subcutaneous adipotide daily for 28 days in obese rhesus monkeys; Reported body-weight loss was in the approximate 7-15% range, often summarized as about 11% over four weeks.
• MRI/DEXA and anthropometric measures supported reduced white adipose tissue, not merely scale-weight change, and insulin-resistance measures improved in the primate study.
• Renal proximal-tubule changes were a central safety signal. The animal study described them as predictable, dose-dependent, and reversible under study conditions; That does not establish safety under unsupervised, chronic, repeated, or human use.
• A published comment questioned whether reduced food intake could explain part of the weight-loss effect. The original authors responded, but the uncertainty stands, and the mechanism is not completely settled.
• The strongest efficacy signal is animal work, especially obese primate data, plus early development history. Human trial initiation does not equal established human obesity efficacy, and it implies no routine human safety profile. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Educational reference only. FDA-label, clinical, preclinical, and community rows are separated when available; These are not medical instructions.

• Protocol 1: Rhesus-Monkey Fixed-Dose Research Protocol [Animal/Preclinical - not a human protocol]; Route: Subcutaneous (SC); Dose: 0.43 mg/kg; Frequency: Daily; Duration: 28 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Community/Anecdotal Research-Market Low-Dose Pattern - Not Equivalent to Primate Protocol [Community/Anecdotal - unvalidated]; Route: Subcutaneous (SC); Dose: 250 mcg – 500 mcg (Total daily); Frequency: Once daily; Duration: 21 to 28 days; Titration/loading: Community reports sometimes describe very low test exposures, but an initial low exposure does not rule out renal risk or validate escalation.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Only SC administration has meaningful published/clinical-development context. Oral, nasal, topical, and transdermal adipotide routes lack route-efficacy support.
• The 0.43 mg/kg daily x 28 days rhesus-monkey protocol is an animal research dose, not a human dose recommendation.
• The initiated Phase 1 human trial was not a general obesity trial; It involved patients with metastatic castration-resistant prostate cancer and obesity/no standard options, with a single 28-day SC cycle, dose escalation, MTD, PK, weight, and disease-progression endpoints.
• Community microgram protocols, where listed, are community/anecdotal research-market patterns, not equivalents to the primate dose and not clinically validated safer regimens.
• Do not infer that a low “test dose” proves kidney safety; Renal injury risk is not ruled out by tolerance of an initial small exposure.
• Animal protocols and community microdose reports are not equivalent. Any dosing discussion needs to state species, route, mg/kg basis, cycle duration, and renal-stop criteria; Otherwise the numbers are misleading. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Human PK is not publicly established well enough for a calculator preset, accumulation estimate, or steady-state model.
• The Phase 1 trial planned PK assessment, but public peer-reviewed PK results were not identified.
• Do not say systemic persistence is limited unless a specific PK dataset is available. A short plasma exposure, if later shown, would not necessarily mean a short biological effect because apoptosis/vascular remodeling can outlast circulating peptide.
• Steady-state, loading-dose, missed-dose, and half-life calculators do not apply to adipotide and return “not applicable/insufficient human PK.”
• Public human PK is insufficient for steady-state or missed-dose calculators. For this compound, pharmacodynamic toxicity and organ exposure matter more than a simple plasma half-life estimate. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Adipotide is not a normal stacking peptide. Its mechanism is pro-apoptotic vascular injury, so “repair,” “hydration,” or antioxidant stacks do not neutralize the central risks.
• There are no validated human data showing safe coadministration with GLP-1/GIP agents, stimulants, diuretics, dehydration protocols, NSAID-heavy use, nephrotoxic drugs, or aggressive calorie restriction.
• If a website stack checker says no obvious conflict, that does not mean same-cycle safety. The limiting issue is not only receptor overlap; It is kidney/perfusion/exposure risk and tissue-injury biology.
• The practical default is “standalone high-risk research compound; No evidence-based stack.”
• Adipotide should not be casually stacked with GLP-1s, diuretics, nephrotoxic agents, stimulants, or dehydration-prone protocols. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Primary known safety concern: renal proximal-tubule toxicity in nonhuman primates. Reversibility in the animal study does not establish a human safety margin.
• Higher concern contexts include reduced eGFR, kidney disease history, proteinuria/albuminuria, dehydration, uncontrolled blood pressure, diabetes with kidney involvement, concurrent nephrotoxic exposure, pregnancy, breastfeeding, active systemic illness, or inability to obtain lab monitoring.
• Cancer is not a simple absolute contraindication here, because the registered human trial was in metastatic prostate cancer. Correct wording: active cancer or cancer history requires physician/clinical-trial oversight and is not a community-use indication.
• Other possible concerns include injection reactions, malaise/fatigue, hypotension or volume issues, nausea/food-intake effects, unexpected tissue injury, and unknown immunogenicity/impurity risks from research-market material.
• Because the active mechanism is injury-based, absence of immediate symptoms is not proof of safety.
• The kidney signal is the gating safety issue. Nausea, dehydration, renal tubular injury, and unintended tissue effects are more relevant than ordinary injection-site concerns. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Monitoring cannot make adipotide clinically validated, but if it were studied, kidney monitoring would be central rather than optional.
• Baseline and follow-up renal markers should include serum creatinine, eGFR, BUN, cystatin C if available, urinalysis, urine albumin-to-creatinine ratio or protein-to-creatinine ratio, electrolytes, hydration status, and blood pressure.
• Metabolic tracking may include body weight, waist circumference, fasting glucose/insulin, A1c when relevant, lipids, and liver enzymes, but these are secondary to renal safety.
• Stop/escalation boundaries in a formal protocol should be based on changes from baseline, not generic “normal ranges.” Any worsening renal marker, new protein/albumin in urine, hematuria, dehydration/hypotension, or systemic illness would be a red-flag event.
• Home scale weight is not enough. The primate efficacy interpretation relied partly on imaging/DEXA/MRI and metabolic measures.
• Monitoring should prioritize renal function, hydration, urine findings, electrolytes, and blood pressure before body-composition enthusiasm. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Adipotide/prohibitin-TP01 is not FDA-approved for obesity or any other indication.
• FDA IND clearance and first-patient dosing were reported in 2012 for a Phase 1 trial, but this is not approval and does not establish clinical efficacy.
• The trial context was metastatic castration-resistant prostate cancer with obesity/no standard options, not ordinary weight-loss care.
• No peer-reviewed human obesity-efficacy results or routine safety dataset were identified. Marketing claims of “human-proven fat loss” are unsupported unless they cite actual published clinical results.
• Do not confuse Adipotide/prohibitin-TP01 with newer “Adipo” programs such as ADPO-002NP; Those involve different mechanisms/products.
• Adipotide is not FDA-approved for obesity or wellness use. Trial-development history is investigational, not validation for the research-market product category. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine. 2004;10(6):625-632. PMID:15133506. Use: Foundational in-vivo phage-display study identifying the CKGGRAKDC prohibitin-homing motif and showing fat-ablation weight loss in obese mice.

2. [C] Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. 2011;3(108):108ra112. PMID:22072637. Use: Rhesus-monkey study showing ~10.6% body-weight loss over 28 days plus reversible, dose-dependent renal tubular toxicity, basis for the entry’s high safety concern.

3. [B] National Cancer Institute Drug Dictionary. Prohibitin-targeting peptide 1. Use: identity, structure, mechanism, oncology context.

4. [C] Barnhart KF et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. 2011;3(108):108ra112. PMID: 22072637. Use: main nonhuman-primate efficacy/safety evidence.

5. [C] Criscione L. Comment on the adipotide monkey paper. Science Translational Medicine. 2012. PMID: 22539771. Use: mechanism/food-intake uncertainty.

6. [C] Salameh A et al. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI Insight. 2016;1(10):e86351. Use: PHB/ANXA2/CD36 mechanistic context.

7. [D] Arrowhead Pharmaceuticals. FDA clearance and first-patient dosing press releases for Adipotide Phase 1. Use: clinical-trial initiation context; company source, not outcome evidence.